CHASAM

Taking Stock in Pfizer Inc.

This is an article that is hard to either heartily disagree with or dismiss as another Pfizer bashing by a less than informed source. Well informed source that has both positive and negative aspects, the kind of approach it is good to see.

The section on drug trials and clinical development was particularly good. The article provides excellent insight into the process and is food for thought for all those "lean pipeline" critics of Pfizer. If someone can tell me who has the strongest pipeline and what drugs in it are going to be even semi-blockbusters ($.5B)I would welcome that information.

I believe that Jeffrey Kindler was a god-send to Pfizer. It is difficult to turn a supertanker (Pfizer)in a tight radius (time). I believe he brings intelligence, foresight and intestinal fortitude (b**ls)to the company, a much needed combination of traits for any companies CEO. I believe the article recognizes this.

When it comes to the rest of Pfizer's senior management, I think that the author is a bit harsh. Personally, I view those assets that the author seems to regard as a hindrance as an asset; well grounded in intelligence and experience. I'll take those characteristics in my company anytime.

Despite my disagreement with some aspects of this article, I must rate it as a plus for overall coverage. We all have our opinions.